Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study

Table 5 Univariate analysis of overall survival before and after propensity score matching

Variable	All patients (n = 144)		Matched patients (n = 72)
	Hazard ratio	P value	Hazard ratio	P value
Age: < 60 yr vs ≥ 60 yr	1.248 (0.669-2.330)	0.486	0.778 (0.308-1.965)	0.595
Sex: Male vs female	0.991 (0.525-1.869)	0.977	0.974 (0.432-2.194)	0.949
Comorbidity: Present vs absent	1.228 (0.664-2.271)	0.513	1.830 (0.782-4.281)	0.163
NAC: Yes vs No	1.466 (0.777-2.768)	0.235	1.709 (0.756-3.816)	0.192
Extent of gastrectomy: Subtotal vs total	1.394 (0.966-1.883)	0.079	1.282 (0.479-3.435)	0.621
Tumor location: Lower vs upper	1.128 (0.507-2.514)	0.767	0.676 (0.218-2.522)	0.676
Tumor location: Middle vs upper	1.750 (0.758-3.832)	0.197	0.758 (0.228-2.522)	0.651
Tumor size: > 5 cm vs ≤ 5 cm	2.429 (1.282-4.603)	0.006	4.765 (1.886-12.038)	0.001
cT stage: T4a/4b vs T3	0.834 (0.461-1.570)	0.548	1.347 (0.575-3.153)	0.492
cN stage: N1-3 vs N0	1.748 (0.839-3.641)	0.136	0.971 (0.332-2.844)	0.957
Lymphovascular invasion: Yes vs No	2.291 (1.233-4.256)	0.009	2.600 (1.141-5.928)	0.023
Neural invasion: Yes vs No	1.390 (0.736-2.652)	0.310	2.304 (0.953-5.567)	0.064
Adjuvant chemotherapy: Yes vs No	0.673 (0.357-1.270)	0.222	0.654 (0.271-1.581)	0.346

NAC: Neoadjuvant chemotherapy.